KITE PRESENTS NEW DATA ON PATIENT OUTCOMES WITH CAR T-CELL THERAPY AT THE 7TH EUROPEAN CAR T-CELL MEETING, 6-8 FEBRUARY, STRASBOURG, FRANCE
Stockley Park, UK – 6 February 2025 – Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR)
T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. Data from Italy demonstrate Kite’s commitment to changing patient outcomes for people living with difficult-to-treat blood cancers through manufacturing excellence and support programmes.
“As the leader in CAR-T cell therapy, Kite is pleased to add to the important scientific exchange during the 7th European CAR T-Cell Meeting, with a focus on improving outcomes for people living with difficult-to-treat blood cancers,” said Dan Tovar, Interim Head of Medical Affairs, Kite, Australia, Canada and Europe (ACE) Region . “These presentations reinforce the importance of support programmes and infrastructure needed to meet the ongoing unmet need for patients and improve healthcare system resources.”
The following Kite spokespeople are available:
- Dick Sundh, Vice President, Head of ACE, Kite
- Dan Tovar, Interim Head of Medical Affairs ACE, Kite
For more information or to arrange an interview contact Cressida Robson on +44 7341 789 204, cressida.robson@gilead.com or Ana Coimbra on +35 193 679 420, Ana.Coimbra@gilead.com .
All posters will be presented on Thursday 6 February – Saturday 8 February 2025, 09:00 -18:00 CET.
|
Abstract Title |
|
CARE-TOGETHER: The First Italian Patient Support Program for CAR T Patients S. Bramanti; A. Chiappella; A. Di Rocco; F. Sorà; E. Ateri;
|
|
Optimizing Care After CAR T-cell Therapy: Reduction of In-hospital Monitoring Duration Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Infusion T. Best; A. Lee; Y. Zheng; J.J. Kim
|
|
Manufacturing Commercial Axicabtagene Ciloleucel (Axi-Cel) in Italy for Patients with Relapsed/Refractory NHL: A 2-Year Retrospective Analysis B. Casadei; M. Ganzetti; F. Torelli; R. Balzano; D. Myers
|
|
Increasing CAR T delivery capacity in Certified Healthcare Facilities: An impact assessment of shifting resources from ASCT to CAR T in second-line treatment of diffuse large B-cell lymphoma M. Shafey; A. Davies; I. Baltadakis; A. Barber; E. Church; A. Laws; B. Doble
|
For more information, please visit: https://www.ebmt.org/events/eha-ebmt-7th-european-car-t-cell-meeting
About Axicabtagene Ciloleucel
Axicabtagene ciloleucel is a CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy, approved by the European Commission (EC) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy; adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy; adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
About Brexucabtagene Autoleucel
In December 2020, the European Commission (EC) granted conditional Marketing Authorisation for brexucabtagene autoleucel, the first CAR T-cell therapy approved in Europe for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. In August 2022, the EC approved brexucabtagene autoleucel for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017.
